Under the terms of the agreement, Cellgate will perform studies to evaluate the feasibility of using its technology to topically deliver ISA247. These studies will commence over the next few months and are expected to be completed over the course of one year.
In exchange for this work, Isotechnika will pay Cellgate a total of $500,000, with $200,000 paid upfront and the remainder at predetermined time points. Upon successful completion of the studies, Isotechnika has the option to license the technology from Cellgate to further develop and commercialize conjugates for topical delivery of ISA247.
“The opportunity to collaborate with Cellgate is very worthwhile,” noted Dr Randall Yatscoff, Isotechnika’s president and CEO. “If successful, this could allow us to expand our drug’s use beyond the moderate and severe forms of psoriasis currently being tested with systemic ISA247 into the milder cases of psoriasis.”